Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis

American Journal of Hematology
Steven M BairJakub Svoboda

Abstract

Patients with relapsed/refractory Hodgkin lymphoma (RR-HL) who progress or relapse following autologous stem cell transplantation (ASCT) have historically had a poor prognosis. Several novel agents, particularly brentuximab vedotin, have shown efficacy in this setting. However, there remains a paucity of data characterizing outcomes outside of clinical trials and how these novel agents have impacted prognosis in general population of patients with RR-HL. Here, we conducted a retrospective analysis to evaluate outcomes in 87 patients with RR-HL with relapse post-ASCT. Treatment with novel agents (including brentuximab vedotin) was associated with significant improvement in median overall survival (OS) compared to patients who did not receive novel agents (85.6 vs 17.1 months; P < .001). Additional factors associated with improved OS in univariate analysis include treatment with radiation therapy post-ASCT (34.1 vs 17.0 months; P = .015), chemosensitivity (i.e., relapsed compared to primary refractory disease; 51.8 vs 25.6 months; p = 0.013), initial response to ASCT (i.e., CR/PR compared to SD/PD; 46.1 vs 20.4 months; P = .011), and transplantation in 2010 and later compared to prior to 2010 (not reached vs 24.5 months; P = .025...Continue Reading

References

Mar 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M G PfreundschuhR Kuse
Aug 1, 1996·Controlled Clinical Trials·M Schemper, T L Smith
Nov 7, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Navneet S MajhailLinda J Burns
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Mar 17, 2010·American Journal of Hematology·Patrick B JohnstonThomas E Witzig
Mar 18, 2011·British Journal of Haematology·Stephen D SmithAlison J Moskowitz
Oct 4, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Panayotis KaloyannidisAchilles Anagnostopoulos
Mar 29, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas YounesRobert Chen
May 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas YounesAndreas Engert
May 29, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C MartínezUNKNOWN Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT) and the Gruppo Italiano Trapianto d
Dec 9, 2014·The New England Journal of Medicine·Stephen M AnsellPhilippe Armand
Mar 17, 2015·Current Medical Research and Opinion·Vijayveer BonthapallyDirk Huebner
Jun 30, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philippe ArmandCraig H Moskowitz

❮ Previous
Next ❯

Citations

Dec 20, 2016·Journal of Internal Medicine·I Glimelius, A Diepstra
May 18, 2019·American Society of Clinical Oncology Educational Book·Alison J MoskowitzAnne W Beaven
Feb 29, 2020·Therapeutic Advances in Hematology·Theodoros P VassilakopoulosMaria K Angelopoulou
Jun 9, 2020·Annals of Hematology·Huseyin BekozBurhan Ferhanoglu
Aug 1, 2019·Cancers·Theodoros P VassilakopoulosKostas Konstantopoulos
Jul 1, 2020·Hematology/oncology and Stem Cell Therapy·Madiha Iqbal, Mohamed A Kharfan-Dabaja
Jul 14, 2021·Leukemia & Lymphoma·Leopoldine LapierreLucie Oberic

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.